COVID-19 Monoclonal Antibody Study
A press release was issued by Eli Lilly on Dec. 4, 2020 about a COVID-19 monoclonal antibody study being conducted in partnership with UnitedHealth Group. The national, 500,000-person pragmatic study will test their new monoclonal antibody treatment for people recently diagnosed with COVID-19. This treatment was authorized by the U.S. Food & Drug Administration for emergency use.
This study will be offered to UnitedHealthcare Medicare Advantage members in 46 states who meet the study’s criteria for participation. Information about the study, including selection criteria and how UnitedHealthcare members can volunteer to be considered for the study, can be found at unitedinresearch.com.
Last update: September 28, 2020, 12:40 p.m. CDT
UnitedHealthcare is working to help people access health care to the fullest extent possible as we come together to address the national public health emergency. We’re adopting measures that will reduce administrative burden for physicians and facilities and help members more easily access the care they need under their benefit plan.
As needed, we’re also adjusting programs and services to protect members and help limit the spread of the COVID-19 virus in communities. We may also temporarily suspend or relax additional policies as needed in regions where inpatient capacity is most compromised and at risk.
Systems are being updated to reflect these changes. Please check back often for the latest information.
We’re committed to keeping you up to date on COVID-19 – we’re monitoring your inquiries and working hard to answer your questions. Let us know how we’re doing.
We’ll be making daily updates to this site. Be sure to check back often for the latest information.
The benefits and processes described on this website apply pursuant to federal requirements and UnitedHealthcare national policy during the national emergency. Additional benefits or limitations may apply in some states and under some plans during this time.
We will adjudicate benefits in accordance with the member’s health plan.
Medicaid Providers: UnitedHealthcare will reimburse out-of-network providers for COVID-19 testing-related visits and COVID-19 related treatment or services according to the rates outlined in the Medicaid Fee Schedule.